Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Parkinson disease

How reliable are prodromal indicators of Parkinson disease?

Nature Reviews Neurology volume 11, pages 5–6 (2015)Cite this article

Subjects

The notion that the classic motor features of Parkinson disease (PD) are preceded by a prodrome has received renewed interest in the past decade. A recent study corroborates previous findings that smell loss and constipation are signifiers of nigral degeneration. But can we really predict who is going to get PD?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ross, G. W., Abbott, R. D., Petrovitch, H., Tanner, C. M. & White, L. R. Pre-motor features of Parkinson's disease: the Honolulu–Asia Aging Study experience. Parkinsonism Relat. Disord. 18 (Suppl. 1), S199–S202 (2012).

    Article  Google Scholar 

  2. Jennings, D. et al. Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study. Neurology 83, 1739–1746 (2014).

    Article  CAS  Google Scholar 

  3. Iranzo, A. et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS ONE 9, e89741 (2014).

    Article  Google Scholar 

  4. Silveira-Moriyama, L. & Lees, A. J. Up with the lark: a panoptic view of Parkinson disease. Neurology 77, 310–311 (2011).

    Article  CAS  Google Scholar 

  5. Pare, P., Ferrazzi, S., Thompson, W. G., Irvine, E. J. & Rance, L. An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am. J. Gastroenterol. 96, 3130–3137 (2001).

    Article  CAS  Google Scholar 

  6. Berg, D., Marek, K., Ross, G. W. & Poewe, W. Defining at-risk populations for Parkinson's disease: lessons from ongoing studies. Mov. Disord. 27, 656–665 (2012).

    Article  Google Scholar 

  7. Ritz, B., Lee, P.-C., Lassen, C. F. & Arah, O. A. Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease. Neurology 83, 1396–1402 (2014).

    Article  CAS  Google Scholar 

  8. Noyce, A. J. et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann. Neurol. 72, 893–901 (2012).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

L.S.-M. has received grants from the Reta Lila Howard Foundation, FAPESP, FAEPEX-UNICAMP, Parkinson's UK and CNPq-CAPES. A.J.L. has received grants from the PSP Association, the Weston Trust and the Reta Lila Howard Foundation. L.S.-M. would like to thank Professor Paulo A. Lotufo for helpful comments about constipation in women.

Author information

Authors and Affiliations

  1. Postgraduate Research Program in Medicine, Universidade Nove de Julho (Uninove), 235/249 Rua Vergueiro, São Paulo, 01504-001, SP, Brazil

    Laura Silveira-Moriyama

  2. University College London, Reta Lila Weston Institute, 1 Wakefield Street, London, WC1N 1PJ, UK

    Andrew J. Lees

Authors
  1. Laura Silveira-Moriyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew J. Lees
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laura Silveira-Moriyama.

Ethics declarations

Competing interests

L.S.-M. has received travel grants from Genus, Ipsen and Abbott. A.J.L. has consulted for Genus, and has served on advisory boards and received honoraria from Novartis, Teva, Meda, Boehringer Ingelheim, GSK, Ipsen, Lundbeck, Allergan, Orion, BIAL, Noscira and Roche.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Silveira-Moriyama, L., Lees, A. How reliable are prodromal indicators of Parkinson disease?. Nat Rev Neurol 11, 5–6 (2015). https://doi.org/10.1038/nrneurol.2014.235

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2014.235

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing